Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant].
Medicine (Baltimore). 2021 Jan 22; 100(3):e23641.M

Abstract

GOALS

To evaluate safety and efficacy of Bacillus coagulans LBSC [DSM17654] in irritable bowel syndrome (IBS) through a prospective, interventional, randomized, double-blind, and placebo-controlled, CONSORT compliant clinical trial.

BACKGROUND

Bacteriotherapy shows promising impact on alleviating clinical conditions of IBS and associated functional gastrointestinal disorders. B coagulans LBSC is a genetically and phenotypically safe probiotic strain used in this study to study its impact on ameliorating IBS symptoms and improving quality of life.

METHODS

In this interventional, randomized, double-blind, placebo-controlled clinical study, total 40 subjects (18-65 years) were screened through Rome IV criteria and randomized into 2 groups, that is, interventional and placebo arm (n = 20/arm). Similar dosages were received by both the arm, that is, placebo (vehicle) and interventional arm (B coagulans LBSC, 6 billion/d) for a period of 80 days. Study completed with per protocol subjects (n = 38) and results were considered to evaluate the primary and secondary endpoints.

RESULTS

Assessment through Digestive Symptom Frequency Questionnaire 5 point Likert scale showed significant improvement in interventional arm compared to placebo on symptoms such as bloating/cramping, abdominal pain, diarrhea, constipation, stomach rumbling, nausea, vomiting, headache, and anxiety. Maximum of "no symptoms" cases and mild to moderate gastrointestinal symptoms along with improved stool consistency were from interventional arm tested following IBS severity scoring system and Bristol stool form scale. Upper gastrointestinal endoscopy revealed no clinical difference of gastrointestinal mucosa between both the arms. B coagulans LBSC was well tolerated with no serious adverse events.

CONCLUSIONS

B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated.

Authors+Show Affiliations

Probiotics Laboratory, Advanced Enzyme Technologies Ltd., Sun Magnetica, Louiswadi, Thane (W), Maharashtra, India.No affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

33545934

Citation

Gupta, Anil Kumar, and Chiranjit Maity. "Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: a Prospective, Interventional, Randomized, Double-blind, Placebo-controlled Clinical Study [CONSORT Compliant]." Medicine, vol. 100, no. 3, 2021, pp. e23641.
Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021;100(3):e23641.
Gupta, A. K., & Maity, C. (2021). Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine, 100(3), e23641. https://doi.org/10.1097/MD.0000000000023641
Gupta AK, Maity C. Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: a Prospective, Interventional, Randomized, Double-blind, Placebo-controlled Clinical Study [CONSORT Compliant]. Medicine (Baltimore). 2021 Jan 22;100(3):e23641. PubMed PMID: 33545934.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. AU - Gupta,Anil Kumar, AU - Maity,Chiranjit, PY - 2020/06/05/received PY - 2020/11/12/accepted PY - 2021/2/6/entrez PY - 2021/2/7/pubmed PY - 2021/2/16/medline SP - e23641 EP - e23641 JF - Medicine JO - Medicine (Baltimore) VL - 100 IS - 3 N2 - GOALS: To evaluate safety and efficacy of Bacillus coagulans LBSC [DSM17654] in irritable bowel syndrome (IBS) through a prospective, interventional, randomized, double-blind, and placebo-controlled, CONSORT compliant clinical trial. BACKGROUND: Bacteriotherapy shows promising impact on alleviating clinical conditions of IBS and associated functional gastrointestinal disorders. B coagulans LBSC is a genetically and phenotypically safe probiotic strain used in this study to study its impact on ameliorating IBS symptoms and improving quality of life. METHODS: In this interventional, randomized, double-blind, placebo-controlled clinical study, total 40 subjects (18-65 years) were screened through Rome IV criteria and randomized into 2 groups, that is, interventional and placebo arm (n = 20/arm). Similar dosages were received by both the arm, that is, placebo (vehicle) and interventional arm (B coagulans LBSC, 6 billion/d) for a period of 80 days. Study completed with per protocol subjects (n = 38) and results were considered to evaluate the primary and secondary endpoints. RESULTS: Assessment through Digestive Symptom Frequency Questionnaire 5 point Likert scale showed significant improvement in interventional arm compared to placebo on symptoms such as bloating/cramping, abdominal pain, diarrhea, constipation, stomach rumbling, nausea, vomiting, headache, and anxiety. Maximum of "no symptoms" cases and mild to moderate gastrointestinal symptoms along with improved stool consistency were from interventional arm tested following IBS severity scoring system and Bristol stool form scale. Upper gastrointestinal endoscopy revealed no clinical difference of gastrointestinal mucosa between both the arms. B coagulans LBSC was well tolerated with no serious adverse events. CONCLUSIONS: B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/33545934/Efficacy_and_safety_of_Bacillus_coagulans_LBSC_in_irritable_bowel_syndrome:_A_prospective_interventional_randomized_double_blind_placebo_controlled_clinical_study_[CONSORT_Compliant]_ L2 - https://doi.org/10.1097/MD.0000000000023641 DB - PRIME DP - Unbound Medicine ER -